Get the Stockscreener App
92.90
0.49%
0.45
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $92.90, with a volume of 1.67M.
It is up +0.49% in the last 24 hours and down -0.45% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$92.45
Open:
$92.525
24h Volume:
1.67M
Relative Volume:
0.31
Market Cap:
$288.04B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.85
EPS:
3.0113
Net Cash Flow:
$9.87B
1W Performance:
+1.69%
1M Performance:
-0.45%
6M Performance:
+32.58%
1Y Performance:
+39.66%
1-Day Range:
$92.18
$92.91
1-Week Range:
$90.63
$93.10
52-Week Range:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
92.90 | 286.65B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Benzinga
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus
AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer - Stock Titan
AstraZeneca (LON:AZN) Insider Sells £40,083.12 in Stock - MarketBeat
FDA grants breakthrough therapy designation to AstraZeneca’s ENHERTU for HER2-positive early breast cancer - Investing.com UK
AstraZeneca PLCUpdate on LATIFY Phase III trial of ceralasertib - Research Tree
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
Jacobio Strikes New Cancer Drug Deal with AstraZeneca - marketscreener.com
AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor - marketscreener.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView — Track All Markets
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometr - GuruFocus
AstraZeneca pulls Andexxa from US market after post-marketing fatalities - Pharmaceutical Technology
Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival - marketscreener.com
AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US - marketscreener.com
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles - Vox Markets
AstraZeneca’s lung cancer trial fails to meet primary endpoint - Investing.com
AstraZeneca’s Enhertu gets FDA Breakthrough Therapy status for breast cancer - Investing.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US - marketscreener.com
AstraZeneca’s ceralasertib fails to meet primary endpoint in lung cancer trial - Investing.com Nigeria
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial - Reuters
AstraZeneca's Lung Cancer Drug Misses Phase 3 Survival Goal - marketscreener.com
AstraZeneca says Latify phase III trial fails to meet primary endpoint in NSCLC - marketscreener.com
AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial - marketscreener.com
AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor - Citeline News & Insights
Jacobio Pharma signs $2 billion license deal with AstraZeneca for cancer drug - Investing.com Nigeria
AstraZeneca PLC $AZN Position Boosted by Benson Investment Management Company Inc. - MarketBeat
Published on: 2025-12-20 18:56:48 - ulpravda.ru
AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims - Law360
Why global investors buy Precidian ETFs Trust AstraZeneca PLC stockRisk Management & Consistent Growth Stock Picks - Улправда
AstraZeneca PLC (AZN) Announces Approval of Saphnelo by the European Union - Insider Monkey
AstraZeneca (LON:AZN) Reaches New 1-Year HighHere's What Happened - MarketBeat
AstraZeneca (AZN) Among Companies Prepping Price Reductions - GuruFocus
AstraZeneca to Halt Andexxa Sales in US Over FDA Safety Concerns - marketscreener.com
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns - GuruFocus
AstraZeneca director gifts 5,735 shares to spouse in off-market transaction - Investing.com India
Voya Investment Management LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
16,277 Shares in AstraZeneca PLC $AZN Bought by Montecito Bank & Trust - MarketBeat
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):